Currently, there are 129.19M common shares owned by the public and among those 117.42M shares have been available to trade.
However, the script later moved the day high at 0.8200, up 9.36%. The company’s stock has a 5-day price change of -1.19% and 15.40% over the past three months. ATRA shares are trading 48.50% year to date (YTD), with the 12-month market performance down to -76.78% lower. It has a 12-month low price of $0.20 and touched a high of $3.43 over the same period. ATRA has an average intraday trading volume of 3.56 million shares. The stock is trading above its simple moving averages at the SMA20, SMA50, and SMA200, as the current price level is off by -0.96%, 7.83%, and -40.20% respectively.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Institutional ownership of Atara Biotherapeutics Inc (NASDAQ: ATRA) shares accounts for 51.41% of the company’s 129.19M shares outstanding.
It has a market capitalization of $98.38M and a beta (3y monthly) value of 0.70. The earnings-per-share (ttm) stands at -$2.77. Price movements for the stock have been influenced by the stock’s volatility, which stands at 11.78% over the week and 12.50% over the month.
Analysts forecast that Atara Biotherapeutics Inc (ATRA) will achieve an EPS of -$0.48 for the current quarter, -$0.47 for the next quarter and -$1.48 for 2024. The lowest estimate earnings-per-share for the quarter is -$0.62 while analysts give the company a high EPS estimate of -$0.31. Comparatively, EPS for the current quarter was -$0.72 a year ago. Earnings per share for the fiscal year are expected to decrease by -9.15%, and 50.58% over the next financial year.
Looking at the support for the ATRA, a number of firms have released research notes about the stock. Mizuho stated their Neutral rating for the stock in a research note on November 09, 2023, with the firm’s price target at $31-$1. Evercore ISI was of a view on November 09, 2023 that the stock is In-line, while Citigroup gave the stock Sell rating on July 20, 2022, issuing a price target of $8- $3. Stifel on their part issued Hold rating on July 13, 2022.
